anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The present invention relates to a Chinese patent medicine mainly used for treating arthritis and a preparation method and a quality control method thereof, particularly to an improved preparation method and an improved quality control method of pills and tablets for dissipating wind and removing dampness. In the method, eight kinds of medicinal herbs, such as dahurian angelica root, etc., are used for extracting a fat-soluble extract A by supercritical CO2; 11 kinds of medicinal herbs, such as radix aconiti, kusnezoff monkshood, etc., and are added to medicine residues B to be extracted by 40 to 80% of alcohol liquid, and an obtained alcohol extract liquid is concentrated to be thick paste; next, the fine powder of 4 kinds of medicinal herbs, such as myrrh, etc. are added to the thick paste; after the thick paste is dried and pulverized, the thick paste is uniformly mixed with the fat-soluble extract A to obtain a medicine E; the medicine E is prepared into an oral preparation according to a conventional technology for traditional Chinese medicine preparations. Measured by liquid-phase chromatography with high efficiency, 1g of dried medicine E comprises at least 1.0 mg of radix paeoniae rubra measured as peony glycoside. The pain relieving function and the inflammation resisting function of the medicine are superior to those of the original medicine for dissipating wind and removing dampness, the medicine has no toxicity of vermilion and asarum volatilization oil, and the dosage of the medicine can be reduced from 1/3 to 1/5 of the dosage of the original medicine. Thereby, the treatment compliance of patients is greatly enhanced.
For a patient, the perspective of a surgical treatment can mean both, hope, and anxiety. In particular the fear of pain during and after surgery can cause tremendous anxiety. In addition, possible side effects of general anesthesia and sedation should be considered, in particular, in patients with multiple comorbidities. The investigators want to help patients to cope with their anxiety and, in addition, minimize risks of surgical procedures including side effects of anesthesia. With this project, the investigators aim to investigate whether topical anesthesia - often used in ophthalmologic surgical procedures - can sufficiently control pain during and after a glaucoma laser procedure compared to intravenous analgosedation. As primary objective, the effectiveness in pain control of analgosedation and topical anesthesia in MP-TLT will be compared. As secondary objective, the effect of the anesthetic protocol used on postoperative visual related quality of life will be investigated.
Cohorts will receive once- or twice-daily doses of CORT113176 lipid capsule formulation by mouth for 14 days. The anticipated exposure will not exceed the highest exposure considered safe and well-tolerated during Part 1. The dose schedule and prandial state will be determined after evaluation of safety and PK data from Part 1. The choice of formulation of CORT113176 to be used in Part 2 will depend on data review for Part 1.
Prodn. of herbal extracts comprises extracting plant material (pref. contg. alkaloids) with an EtOH/H2O/CO2 mixt. under pressure.  The plant material e.g comprises the green parts of Chelidonium majus, labelia, sarothamnus, ephedra or eschscholtzia, the leaves or roots of belladonna, the leaves of hyoscyamus or stramonium, the roots of rauwolfia or ipecacuanha, or Secale cornutum.
Detailed Summary: Bone disease has been a well-recognized complication of renal disease for over 100 years. Until the advent of dialysis, however, it was only another of the many dreadful complications of a fatal disease. Almost since the onset of dialysis, however, bone disease and calcium metabolism presented major difficulties to patients and physicians. Recently we reported that dialysis patients had an 8-fold increase in hip fracture rate, compared to the normal population. In younger dialysis patients (age 30-50 years) this risk was increased to nearly 100 fold. We have also noted a similar or even higher incidence of fracture in the transplant population. Low bone mass has been found in dialysis patients by ourselves and other investigators, a finding in the general population which predisposes to fracture. In the dialysis population, bone histologic studies done by us and others have reported the adynamic (low turnover) lesion in more than half of the dialysis population. This lesion is similar to what is seen in osteoporosis. Thus, dialysis patients, like osteoporotics, have low bone mass, low bone turnover, and a high fracture rate. In the osteoporotic patients, various bisphosphonates have been shown to inhibit bone resorption, increase bone mass and decrease fracture rate. The only bisphosphonate approved for use in patients with renal failure is pamidronate. This agent has not been used extensively in the general population because it must be given intravenously. This, together with the fact that pamidronate has a bone half-life of over 300 days, actually makes this drug a strong candidate for the treatment of patients with renal failure. In this investigation we propose using pamidronate in patients with renal failure to prevent bone loss and fracture. We will monitor bone mass by DEXA in patients to assess treatment response, assess bone histology in selected subjects, and collect data on fractures in the population.

Comparison: Subjects with normal or low parathyroid hormone (PTH) who receive dosing with pamidronate will be compared to similar subjects who receive placebo. Comparison groups will be randomly assigned and assignment will be blind.
Identified herein is a novel post-translational modification of Mcm2, wherein the residue of serines 53 and 108 are phosphorylated. DDK phosphorylates Mcm2 at serines 53 and 108 when stimulated by Treslin. DDK is overexpressed in many human cancers, including colorectal cancer, suggesting that monitoring the phosphorylation of Mcm2 at serines 53 and 108 may detect early cancer with high sensitivity and specificity. It was also found that the homologous modification in budding yeast is required for DNA replication, and the modification occurs in cells during active DNA replication only. In an embodiment, the current invention is an antibody specific for human Mcm2 that is phosphorylated at serines 53 and 108. This antibody was found to be overexpressed in colon cancer cell line HCT 116, as well as other cancer cell lines, compared to normal cells.
Bevacizumab (10 mg/kg) i.v. is given every two weeks. Paclitaxel (90 mg/m2) i.v. is given on days 1, 8, and 15 of a 4 week cycle. Both medications are given until PD, unacceptable adverse event, or consent withdrawal. If an unacceptable adverse event to any of the drugs in this treatment arm occurs the remaining tolerated drug is given until PD, consent withdrawal, or unacceptable adverse event according to local investigators opinion.
The cellular prion protein (PrPC) is an extracellular cell membrane protein. Due to its diversified roles, a definite role of PrPC has been difficult to establish. During viral infection, PrPC has been reported to play a pleiotropic role. Here, we have attempted to envision the function of PrPC in the neurotropic m-CoV-MHV-RSA59-induced model of neuroinflammation in C57BL/6 mice. A significant upregulation of PrPC at protein and mRNA levels was evident in infected mouse brains during the acute phase of neuroinflammation. Furthermore, investigation of the effect of MHV-RSA59 infection on PrPC expression in specific neuronal, microglial, and astrocytoma cell lines, revealed a differential expression of prion protein during neuroinflammation. Additionally, siRNA-mediated downregulation of prnp transcripts reduced the expression of viral antigen and viral infectivity in these cell lines. Cumulatively, our results suggest that PrPC expression significantly increases during acute MHV-RSA59 infection and that PrPC also assists in viral infectivity and viral replication.
Fever in infants presenting to pediatric emergency departments (PEDs) often results in significant return visits (RVs). This retrospective study aimed to identify factors associated with RVs in febrile infants aged 0 to 90 days. Data from infants presenting to PED between 2018 and 2021 and returning within 7 days (RV group) were compared to age-matched febrile infants without RVs (control group). Each group had 95 infants with similar demographics and medical history. RVs were primarily due to positive cultures and persistent fever. The control group had higher initial hospitalization rates, longer PED stays, and increased antibiotic treatment. Prevalence of serious bacterial infections (SBIs) did not significantly differ. Higher hospitalization, prolonged PED stays, and initial antibiotic treatment were associated with reduced RV incidence despite similar SBI rates. Return visits in infants <90 days were primarily driven by persistent fever and positive cultures. Addressing these factors through targeted parental education and improved care protocols may reduce RVs.
Telemedicine uses communications technologies to provide health care when distance separates participants. Applied to general medical care practice, telemedicine is associated with improved continuity of care, cost-effectiveness, and improved service quality. To date, all evaluations of telepsychiatry have concentrated on video technology. The telephone is more readily available and less expensive communication technology that has not been evaluated as a method of health services delivery in the medication management of stable psychiatric outpatients. We will enroll 346 psychiatrically stable subjects, who carry a diagnosis of major depression, post-traumatic stress disorder (PTSD) or non-PTSD anxiety disorder. We will use a balanced randomization strategy to assign subjects to routine care or telephone care for a two-year period within each provider panel. Patients randomized to receive routine care will be scheduled to see their psychiatric medication provider at the recommended interval. Patients randomized to receive telephone care will be scheduled to see their provider at twice the recommended clinic visit interval, and two ten-minute telephone contacts will be scheduled at a specific time at standard 0.67 and 1.3 times the multiple of the recommended interval. At two years, we will use ten data sources to compare two primary outcomes (total VHA health services utilization and mental health component scores from the SF-12-V) as well as VHA costs, imputed non-VHA costs, patient and provider satisfaction, medication compliance and diagnosis specific outcomes.
Subjects meeting COHORT 2 inclusion criteria, clinically diagnosed by the treating provider using that treating provider's standards of diagnosing ACS, and in addition to being diagnosed with ACS, the subject undergoes four-compartment leg fasciotomy. data collection to start BEFORE fasciotomy and continue AFTER fasciotomy.
Autologous T cell vaccines and methods for their production are described. Also described are methods for treating T cell associated diseases such as multiple sclerosis and rheumatoid arthritis using the autologous T cell vaccines. The figure shows that the precursor frequency of circulating MBP-reactive T cells detected in MS patients at baseline (14x 10-5) was highly comparable to that reported in previous studies (approximately 10 x10-5 in peripheral blood mononuclear cells) (Zhang et al., 1994, Ota et al., 1990). No significant difference was found in the precursor frequency of MBP-reactive T cells between RR-MS and SP-MS cohorts. The T cell frequency was undetectable in 92% of patients or declined substantially in the remaining patients 2-3 months after the completion of three courses of vaccination (14x10-5 VS. 1.9x 10-5, p < 0.0001). The results confirmed depletion of MBP-reactive T cells by T cell vaccination in patients with MS.
The invention relates to an ANN-based intelligent assessment triage system and method. The intelligent assessment triage system at least comprises an intelligent assessment triage module and an intelligent handheld device. The intelligent assessment triage module can interact with a user to generate triage information. The intelligent handheld device can be in data connection with the intelligent assessment triage module to acquire triage information. The intelligent assessment triage module can determine the disease according to the preliminary diagnosis of the patient, determine the traveling route of the disease on the in-hospital two-dimensional map corresponding to the triage information, and provide the traveling route of the two-dimensional map to the intelligent handheld device of the user. The intelligent handheld device for providing the traveling route of the two-dimensional map to the user comprises: the central server determines the predicted travel time information corresponding to the travel route of the two-dimensional map according to the information of the density of the personnel provided by the monitoring camera in data connection with the central server. The intelligent assessment triage method can be used for the intelligent assessment triage system.
The subjects in this group will receive 3 times per week, and 4 weeks of continuous intervention for a total of 12 times. The intervention including electroacupuncture(EA) treatment and combined with Carbamazepine (0.1g each time, thrice daily). The follow-up period is 6 months.
FIELD: medicine. ^ SUBSTANCE: invention refers to medicine, namely to hepatology, and can be used in treating moderately active and replicative chronic viral hepatitis type C of 1-genotype. That is ensured by parenteral introduction of interferon- in dosage 3 million IU and interferon- in dosage 500 thousand IU every second day and daily double oral introduction of Ribamidyl in dosage 15 mg per kg of body weight. Every 3 months, the interferon therapy is recessed for 10-12 days. Over this period, the preparation Derinat is administered daily. The total therapeutic course is 9 months and 20-24 days, and combined introduction of interferon- and interferon- are performed within the first 6 months. For the next 3 months, interferon-a is administered. Ribamidyl is required for the whole therapeutic course. ^ EFFECT: higher clinical effectiveness and prevention of interferon-resistance development. ^ 2 tbl, 4 ex
Patients undergo leukapheresis from which peripheral blood mononuclear cells are purified. T cells are activated and then re-engineered to express chimeric antigen receptors (CARs) specific for CEA. Cells are expanded in culture and returned to the patient by percutaneous hepatic artery infusion at specific cell doses. Prior to the first dose, each patient will undergo diagnostic angiography to verify suitable arterial anatomy. Three anti-CEA CAR-T doses per patient are planned at 1-week intervals. Low dose interleukin-2 will be given via an ambulatory infusion pump for 4 weeks. Normal liver and tumor biopsies will be obtained at the time of the initial diagnostic angiogram and during the final session following the 3rd CAR-T infusion.

Patients with CEA+ liver metastases who exhibit in-liver control following CAR-T therapy who also have CEA+ primary pancreatic tumors may be eligible to receive direct intrapancreatic CAR-T retrograde venous infusions. A maximum of 2 infusions will be delivered. No additional IL-2 will be given and there will be no additional biopsies.
BACKGROUND: Gastrectomy for gastric cancer is associated with postoperative changes in cardiovascular risk factors, however, the impact of gastrectomy on cardiovascular events remains unclear. The authors assessed the incidence of cardiovascular events between patients undergoing gastrectomy or endoscopic resection for gastric cancer, and the general population.
MATERIALS AND METHODS: This retrospective nationwide cohort study included patients with gastric cancer undergoing gastrectomy ( n =37 698), endoscopic resection ( n =2773), and matched control population ( n =161 887) between 2004 and 2013. The authors included patients without a history of cancer other than gastric cancer, myocardial infarction, or ischemic stroke. The primary outcome was the incidence of major adverse cardiovascular events (MACE) such as acute myocardial infarction, revascularization, or acute ischemic stroke, in patients with gastric cancer.
RESULTS: Among patients who underwent gastrectomy for gastric cancer, 2.9% (4.69 per 1000 person-years) developed novel MACE within the 1-year follow-up period. The gastrectomy group demonstrated a significantly decreased risk for MACE than the control population [hazard ratio (HR), 0.65; 95% CI: 0.61-0.69; P <0.001). Among the patients undergoing endoscopic resection for gastric cancer, 5.4% (8.21 per 1000 person-years) developed novel MACE within the 7-year follow-up period. The risk for MACE in the endoscopic resection group was not significantly different from the control population.
CONCLUSION: Patients with gastric cancer who have undergone gastrectomy exhibit a reduced risk of cardiovascular diseases in comparison to the general population. In contrast, the risk for cardiovascular diseases in patients with gastric cancer who underwent endoscopic resection did not demonstrate a significant difference in cardiovascular risk in comparison to the general population.
The invention belongs to the field of functional hydrogels, and relates to a dynamic nano-enzyme hydrogel, a preparation method and application thereof. The invention passes through the crustThe plain nanofiber is coordinated and complexed with metal Zn salt, self-assembled to form a nano sheet, and pyrolyzed to form an ultrathin hierarchical pore carbon nano sheet (SACs-Zn-PCN) carrying Zn single atoms. The construction of the full biomass-based monoatomic nano-enzyme multifunctional hydrogel is realized by utilizing modified natural polysaccharide CECT-ADH and OD. SACs-Zn-PCN has peroxidase-like activity and high efficiency in catalyzing H  2  O  2  Reactive Oxygen Species (ROS) are generated, so that bacteria resistance is effectively prevented. Meanwhile, the monoatomic Zn synergistically promotes the dynamic reaction of the acylhydrazone bond in the slightly acidic environment, shows dynamic characteristics, and endows the hydrogel with better self-healing property, self-adaptability and injectability. The nano-enzyme hydrogel has wide application prospect and market value in the aspect of promoting healing of infected wounds.
Disclosed techniques relate to memory space management for graphics processing. In some embodiments, first and second graphics cores are configured to execute instructions for multiple threadgroups. In some embodiments, the threads groups include a first threadgroup with multiple single-instruction multiple-data (SIMD) groups configured to execute a first shader program and a second threadgroup with multiple SIMD groups configured to execute a second, different shader program. Control circuitry may be configured to provide access to data stored in memory circuitry according to a shader memory space. The shader memory space may be accessible to threadgroups executed by the first graphics shader core, including the first and second threadgroups, but is not accessible to threadgroups executed by the second graphics shader core. Disclosed techniques may reduce latency, increase bandwidth available to the shader, reduce coherency cost, or any combination thereof.
In phase 1 studies involving 96 patients with various nonmyeloid malignancies‚ NEUPOGEN administration resulted in a dose-dependent increase in circulating neutrophil counts over the dose range of 1 to 70 mcg/kg/day. This increase in neutrophil counts was observed whether NEUPOGEN was administered intravenous (1 to 70 mcg/kg twice daily)‚ subcutaneous (1 to 3 mcg/kg once daily)‚ or by continuous subcutaneous infusion (3 to 11 mcg/kg/day). With discontinuation of NEUPOGEN therapy‚ neutrophil counts returned to baseline in most cases within 4 days. Isolated neutrophils displayed normal phagocytic (measured by zymosan-stimulated chemoluminescence) and chemotactic (measured by migration under agarose using N-formyl-methionyl-leucyl-phenylalanine [fMLP] as the chemotaxin) activity in vitro.

The absolute monocyte count was reported to increase in a dose-dependent manner in most patients receiving NEUPOGEN; however‚ the percentage of monocytes in the differential count remained within the normal range. Absolute counts of both eosinophils and basophils did not change and were within the normal range following administration of NEUPOGEN. Increases in lymphocyte counts following NEUPOGEN administration have been reported in some normal subjects and patients with cancer.

White blood cell (WBC) differentials obtained during clinical trials have demonstrated a shift towards earlier granulocyte progenitor cells (left shift)‚ including the appearance of promyelocytes and myeloblasts‚ usually during neutrophil recovery following the chemotherapy-induced nadir. In addition‚ Dohle bodies‚ increased granulocyte granulation‚ and hypersegmented neutrophils have been observed. Such changes were transient and were not associated with clinical sequelae, nor were they necessarily associated with infection.
Motivational deficits have emerged as a critical determinant of functional disability in schizophrenia (SZ). Despite significant advances in our understanding and treatment of the illness, effective therapeutic strategies for motivational deficits have remained elusive. This has ultimately hindered our ability to promote recovery for individuals with SZ so that they can return to their premorbid level of functioning. An emerging therapeutic approach in SZ has utilized computerized remediation strategies, with recent efforts focused on cognitive deficits. To date, however, such a therapeutic strategy has not been developed for the critical motivational deficits in SZ. In light of the detrimental functional consequences of motivational deficits in SZ, there is a clear need for effective therapeutic strategies for the treatment of these motivational deficits experienced by affected individuals. To address this unmet therapeutic need, this pilot therapeutic trial will investigate the efficacy of a novel virtual reality-based motivation rehabilitation program in schizophrenia.
Ten sessions (every other day) of placebo control (sham procedure) of transcranial Direct Current Stimulation (sham-tDCS) during 20 minutes with electrodes placed over the dorsolateral Prefrontal Cortex (cathodal left / anodal right). Current was delivered for 20 seconds and was turned off for the rest of the stimulation period. In this way, subjects experienced the initial itching sensation at the beginning of stimulation, but received no current for the rest of the session.
Group C: 6 subjects to receive a single, oral dose of ACT-281959 prodrug formulation I and 2 subjects to receive a single, oral dose of matching placebo. Medication to be administered in the fasted state. Dose selection will be based on pharmacokinetic data derived from Groups A-B.
PURPOSE:To obtain an agent exhibiting optimum mechanical disintegrability according to the use to develop the medicinal action in use and stable over a long period by covering a water-soluble agent having medicinal action with a water-insoluble substance, thereby suppressing the dissolution of the agent. CONSTITUTION:An organic solvent solution of a water-insoluble substance (e.g. fatty acid, fatty acid derivative, oil, fat and resin) is sprayed to solid particles of a water-soluble medicinal agent while fluidizing the particles and the solvent is evaporated to form a coating layer of the water-insoluble substance on the surface of the solid particle. The thickness of the coating layer is 10-95mum, preferably 20-80mum. The medicinal agent in the obtained particle is dissolved in an amount of <=5% (preferably <=3%) when left standing in water at 20 deg.C for 30 days and <=10% (preferably <=5%) when left standing in water at 20 deg.C for 90 days. The amount of the water-insoluble coating substance applied to the particle is preferably 1-10,000 pts.wt., especially 5-2,000 pts.wt. based on 1 pt.wt. of the substance having medicinal action.